GlassScriptPhysician profile
Kunal Malhotra
NPI 1720236904
$18,222.57
in general payments reported to CMS, 2019-2025
20 companies · $6,987 in 2025
The $6,987 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $44.78 · 2022: $68.02 · 2023: $6,159 · 2024: $4,560 · 2025: $6,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,048 · Consulting Fee: $4,100 · Travel and Lodging: $2,720 · Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,048.00 |
| Consulting Fee | $4,100.00 |
| Travel and Lodging | $2,719.82 |
| Food and Beverage | $1,838.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $11,085.56 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $3,694.41 | 2023 | Velphoro, Crit-Line |
| Calliditas Therapeutics US INC. | $2,124.47 | 2023 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $244.57 | 2019-2023 | |
| Travere Therapeutics, INC. | $199.87 | 2023-2025 | |
| Amgen INC. | $183.57 | 2024 | Parsabiv, Epogen, Aranesp |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Glaxosmithkline, LLC. | $96.99 | 2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $95.42 | 2020-2024 | Farxiga |
| Baxter Healthcare | $67.07 | 2019-2024 | Renal - Pd |
| Akebia Therapeutics INC | $60.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $51.88 | 2024-2025 | |
| Medtronic, INC. | $44.20 | 2023 | Argyle |
| Otsuka America Pharmaceutical, INC. | $40.83 | 2019-2023 | Jynarque |
| Chiesi USA, INC. | $31.19 | 2023 | Elfabrio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $27.13 | 2025 | Renal - Pd |
| Genzyme Corporation | $24.97 | 2019 | |
| Horizon Therapeutics Plc | $21.20 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $15.70 | 2019 | |
| Genentech USA, INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunal Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.